Fingerprint
Dive into the research topics of 'A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer
Alex A. Adjei, Grace K. Dy, Charles Erlichman, Joel M. Reid, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, Pamela J. Atherton, Tanya Watanabe, Richard S. Geary, Jon Holmlund, F. Andrew Dorr
Research output: Contribution to journal › Article › peer-review
79
Scopus
citations